Data investigation
Not Taking It and Not Tolerating It
Real-world studies usually measure adherence and stopping separately, with every kind of stopping counted the same way. That merges someone whose body cannot tolerate the drug with someone not taking it reliably. A Scottish study separated them and found different predictors.
Real-world studies of these drugs usually measure adherence and stopping as separate outcomes, with every kind of stopping counted the same way. That merges two different situations: someone whose body cannot tolerate the drug, and someone who is not taking it reliably. A Scottish study combined the measures to separate them, and found they have different predictors.[1] So they need different responses, yet the usual measures do not tell them apart.
Why splitting them matters
A person who vomits every time they inject and gives up has a pharmacological problem. A person who keeps meaning to refill and does not has a logistical one. Both appear in a database as a discontinuation, and both get counted in the persistence figures this register has reported.
The interventions are opposite. The first needs a slower titration, a lower dose, or a different drug, and that kind of change has randomized evidence behind it. The second needs reminders, cheaper refills, or fewer barriers between the prescription and the pharmacy. Applying either to the wrong person achieves nothing.
This study classified every treatment start in a national diabetes database into five mutually exclusive groups over one year: adherent, poor adherence, and three ways of discontinuing including a proxy for intolerance.
The two profiles
| Pattern | Associated with |
|---|---|
| Poor adherence | Younger age; previous GLP-1 use |
| Intolerance | Lower BMI; female sex; more advanced chronic kidney disease |
Two ways of ending treatment, and almost nothing in common between them.
If that is what is happening, it is directly actionable: the people most likely to be driven off these drugs by side effects are the ones for whom a slower or lower titration should be considered first. Nothing in this study tests that, but it is the obvious hypothesis the study generates.
The chronic kidney disease association is less clear-cut. The authors suggest it may apply mainly to the drugs the kidneys clear, exenatide and lixisenatide, rather than to the whole class, and lixisenatide was the drug most associated with intolerance here.[1]
The finding that turns up twice
Female sex predicted intolerance here. In a separate US cohort we covered, women had lower odds of both persistence and adherence over twelve months (see less than half are still taking it).
The two studies used different countries, databases and measures, and they point the same way. That is worth more than either finding alone. It also runs against how this field is usually framed: trials over-recruit women, and the public conversation about these drugs is largely about women taking them.
Neither study explains it. If the lower-BMI mechanism is real, part of the answer may be that women are on average lighter and therefore receive more drug per kilogram at the same dose. That would make the sex finding a body-size finding in disguise. It remains a hypothesis, and testing it would require dosing by weight, which nobody does. One semaglutide analysis found women reported more nausea than men even at matched drug levels; see GLP-1 side effects in women vs men.
The drug-by-drug part, and why to hold it loosely
Newer agents showed more favorable usage patterns. Poor adherence was more frequent with liraglutide, lixisenatide and exenatide than with semaglutide, and intolerance was most common with lixisenatide.
One more caution on the whole analysis: intolerance here is a proxy, inferred from the shape of prescribing records rather than read from a recorded diagnosis. Nobody wrote down that these patients could not tolerate the drug; the pattern of their prescriptions suggested it.
Frequently Asked Questions
References
- 1.Donnelly LA, Singh K, McCrimmon RJ, et al. One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population Diabetes, Obesity and Metabolism. 2026. PMID: 41189335.
Compare the sellers
Related research
Five Clicks Instead of a Quarter Milligram
One in five people on the label's titration schedule quit because of gut side effects. On a slower schedule it was one in fifty, at the same final dose, with the same results.
7 min read
Can You Lower the Dose and Keep the Weight Off?
Stepping down to 5 mg held 16.6% of body weight lost against 21.9% for staying at the full dose. But rescue therapy went from 8% to 25%, and to 67% on placebo.
6 min read
Every Other Week: Stretching the Interval
Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.
5 min read
The Cardiovascular Cost of Stopping
A review argues that weight and blood sugar fluctuation are themselves cardiovascular risk factors, and that these drugs do not stabilize arteries the way statins do. It also says few data exist on hard outcomes after stopping.
5 min read
What People Actually Do After Stopping
Average weight change in the year after stopping was +0.5% for people treated for obesity, and −1.3% for those treated for diabetes. That does not contradict the withdrawal trials. It answers a different question.
5 min read
Stretching Doses to Save Money
At list prices above a thousand dollars a month, people stretch these drugs. Two papers argue fortnightly dosing keeps most of the weight loss, on a mathematical model and a case series of two patients.
8 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
MyDrHank
An oral route if you will not self-inject
From $171/mo, prepaid
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →